BioMed Research International / 2019 / Article / Tab 5 / Research Article
Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment Table 5 Extent of marker elevations (x-fold of ULN) in relation to tumour size in CS1 patients.
bHCG [x-fold of ULN] AFP [x-fold of ULN] LDH [x-fold of ULN] Tumour size categories (cm) n (%) Min Median (Q1 - Q3) Max Min Median (Q1 - Q3) Max Min Median (Q1 - Q3) Max Nonseminoma <=1 8 (10.0%) 0.34 0.52 (0.41 - 5.25) 31.69 0.22 0.43 (0.23 - 1.02) 1.79 0.64 0.77 (0.70 - 0.87) 1.22 >1-2 29 (36.3%) 0.03 0.45 (0.41 - 2.34) 49.66 0.14 0.62 (0.25 - 2.16) 22.48 0.55 0.76 (0.67 - 0.89) 1.44 >2-4 26 (32.5%) 0.03 1.97 (0.45 - 4.89) 560.26 0.10 5.58 (1.53 - 17.13) 93.72 0.59 0.81 (0.74 - 0.96) 1.25 >4-6 11 (13.8%) 0.17 0.56 (0.31 - 10.37) 64.54 1.14 11.79 (2.34 - 28.86) 68.14 0.68 0.96 (0.78 - 1.00) 1.46 >6 5 (6.3%) 0.86 2.21 (1.02 - 16.31) 83.90 38.39 194.00 (144.88 - 277.50) 1630.46 0.57 1.11 (1.06 - 1.18) 2.71 p- 0.0673 <.0001 0.0742 All GCT <=1 33 (11.7%) 0.03 0.45 (0.41 - 0.46) 31.69 0.08 0.34 (0.22 - 0.52) 2.12 0.55 0.80 (0.71 - 1.00) 2.81 >1-2 91 (32.4%) 0.03 0.45 (0.41 - 0.45) 49.66 0.05 0.31 (0.22 - 0.59) 22.48 0.51 0.79 (0.68 - 0.89) 1.62 >2-4 87 (31.0%) 0.03 0.45 (0.41 - 2.08) 560.26 0.08 0.36 (0.23 - 1.07) 93.72 0.38 0.81 (0.74 - 0.92) 1.28 >4-6 46 (16.4%) 0.03 0.70 (0.41 - 1.58) 64.54 0.11 0.42 (0.22 - 1.14) 68.14 0.67 0.90 (0.77 - 1.05) 1.81 >6 23 (8.2%) 0.19 2.07 (1.02 - 6.99) 83.90 0.17 0.34 (0.24 - 0.49) 1630.46 0.01 1.11 (0.94 - 1.50) 5.41 p- <.0001 0.4388 <.0001
Mann-Whitney U Test for comparisons of subgroups.